By, Mark Farrar, Katie Norris, Casey Horton, Kiley Kio, Heather Pascanik and Greg Mills
Compliance professionals from more than 200 life science companies gathered virtually to attend the 17th Annual CBI Pharmaceutical Compliance Congress (PCC). Conference presenters, including our experts Saul B. Helman and Ann Beasley, focused on ways to improve compliance programs in 2020 amidst the face of disruptive change and moving forward into 2021.
Conversations with Guidehouse Leaders
Our experts Saul Helman and Ann Beasley spoke with trusted industry professionals about risk assessment and with industry counsel and experienced federal prosecutors, including former Deputy Attorney General Rod Rosenstein, about areas of emerging compliance risk areas during this year’s conference. Below are some key takeaways from their sessions and others:
Empowering Compliance Effectiveness in a New Age
Amid growing pressure to perform and a shift in the way we conduct business, there are several key takeaways to ensuring compliance has a front row seat:
Emerging Trends
There are several emerging trends that highlight compliance risk areas and avenues of future strength:
Importance of Diversity & Inclusion
The life sciences industry is not exempt from recognizing the benefits of diversity and inclusion: